Dutch Medical Technology Firm Secures

2026-07-29 bio

Eindhoven, Wednesday, 29 July 2026.
No Intro Provided

Millions in New Capital for Restorative Vascular Implants

In the rapidly evolving healthtech sector, Dutch clinical-stage medical device company Xeltis has secured €20.5 million, which is equivalent to approximately $23.3 million, in a new funding round to advance its restorative cardiovascular implants [1][2]. This latest capital injection was led by new investor Horizon 3 Healthcare, alongside participation from existing and prominent backers including the European Innovation Council (EIC), Invest-NL, VI Partners, EQT Life Sciences, and DaVita [1][4]. The funding will be primarily utilized to finalize the ongoing United States pivotal clinical trial for its flagship vascular access conduit, aXess, while preparing for U.S. Food and Drug Administration (FDA) submission and subsequent market commercialization [1][2].

A Strong Financial Foundation in Eindhoven

Headquartered in Eindhoven, the Netherlands, Xeltis operates at the intersection of advanced materials science and clinical medicine [2][3][5]. Led by Chief Executive Officer Eliane Schutte, the company has built a robust financial foundation, with this €20.5 million round closely following a €50 million funding round secured in late 2025 from the European Investment Bank and existing shareholders [1][2][4]. This brings the total capital raised across these two recent funding initiatives to €70.5 million, demonstrating strong and sustained investor confidence in the company’s clinical and commercial strategy [4][5][6].

Transforming Hemodialysis Through Restorative Healthtech

The core of Xeltis’ breakthrough lies in the healthtech and medical device space, specifically targeting the complex needs of patients undergoing hemodialysis [3][5]. Hemodialysis is a life-sustaining treatment that filters and cleanses the blood of individuals whose kidneys have failed, requiring reliable and frequent vascular access [5]. To address this, Xeltis has developed the aXess vascular conduit using its proprietary Restorative supramolecular polymer technology [3]. This innovative technology utilizes a bioresorbable, non-immunogenic synthetic implant designed to act as a temporary scaffold [3]. Once implanted, the porous structure of the scaffold enables the patient’s own cells to migrate into the device, gradually transforming the artificial conduit into a living, functional blood vessel made of the patient’s own tissue as the polymer safely resorbs [3].

Addressing the Limitations of Traditional Access

This restorative approach offers significant advantages over traditional vascular access methods [3]. Currently, hemodialysis patients rely on either an arteriovenous fistula (AVF), which requires a lengthy maturation process, or synthetic arteriovenous grafts (AVG), which are highly prone to complications [2]. The aXess conduit successfully bridges this gap by combining the long-term safety and high patency rates of an AVF with the rapid utility and short treatment pathway of an AVG [2]. The implant requires a brief 14-day maturation period post-implantation before it is fully ready for cannulation [3]. By enabling the natural creation of living tissue, the technology aims to dramatically reduce common dialysis-related complications, such as thrombosis, infection, long-term calcification, stenosis, and the frequent need for invasive reinterventions [2][3].

Commercial Milestones and Global Clinical Progress

The fresh capital arrives at a time of significant clinical and commercial momentum for the Eindhoven-based scale-up in July 2026 [2][5]. Earlier this month, Xeltis officially initiated the commercial rollout of the aXess device in Europe, marked by the successful treatment of its first commercial patient in Germany [1][2]. Simultaneously, the company has made rapid progress across the Atlantic, where enrollment in its U.S. pivotal clinical trial has officially surpassed the 50% milestone [1][4]. Beyond the U.S. trial and European commercialization, the €20.5 million funding will support the upscaling of Xeltis’ manufacturing capabilities and the clinical advancement of its broader pipeline, which includes the XABG and XPAD restorative implant programs [2][4][6].

Strong Institutional Backing and Future Outlook

Industry leaders and institutional backers have highlighted the disruptive potential of Xeltis’ platform within the global medical device ecosystem [1][4]. Matt McNamara, Chief Investment Officer of Horizon 3 Healthcare, noted that the clinical data generated by Xeltis to date is highly compelling and underscores the potential of aXess to transform the hemodialysis landscape [1]. Meanwhile, Hermann Hauser, a board member of the EIC Fund, emphasized that while traditional implants rely on permanent synthetic or biological replacements, Xeltis’ ability to enable implants to gradually transform into a patient’s own living tissue represents a paradigm shift in breakthrough medical innovations [1][4]. This support from major European and global investors positions Xeltis to successfully navigate its upcoming FDA submission and expand its life-changing technology to patients worldwide [1][2][6].

Bronnen

medtech innovation cardiovascular devices